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Abstract
Background: At the time of diagnosis, giant gastric gastrointestinal stromal tumors are sometimes associated with
severe peritoneal dissemination. Unresectable gastrointestinal stromal tumors are considered a systemic disease;
therefore, imatinib therapy is currently the primary treatment option in these cases.
Case presentation: A 49-year-old Japanese woman was referred to our hospital with symptoms of anorexia,
abdominal discomfort, and a palpable abdominal mass. Contrast-enhanced computed tomography revealed a huge
mass with an irregular wall, approximately 22 cm in size, located between the posterior gastric wall and her pancreas.
The tumor grew rapidly, and her abdominal symptoms worsened; therefore, a semi-urgent laparotomy was performed.
The tumor had arisen from her upper stomach and was removed by wedge resection of her stomach. In addition,
widely distributed multiple white nodules were noted, which were resected as far as possible. Immunohistochemical
staining of the resected specimen was positive for KIT and CD34. The resected white nodules contained the same cells
as the primary tumor. Based on these pathological findings, a final diagnosis of a gastric gastrointestinal stromal tumor
with peritoneal dissemination was made. Imatinib was administered at 400 mg per day from 1 month postoperatively.
The disease progression of the residual disseminated lesions was favorably controlled, and our patient is now doing
well, 12 months after surgery.
Conclusions: Imatinib therapy following debulking surgery can show dramatic effectiveness in giant gastric
gastrointestinal stromal tumors with severe peritoneal dissemination.
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Background
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the gastrointestinal
tract [1]. Primary GISTs can arise anywhere along the
gastrointestinal tract; however, a majority arises in the
stomach (50 to 60 %) [2]. Gastric GISTs are clinically
asymptomatic until they reach a significant size; there-
fore, a majority of GISTs are incidentally discovered
either by diagnostic tests or during abdominal surgery.
Giant gastric GISTs are infrequently associated with
symptoms such as abdominal pain, digestive bleeding,
and a palpable mass [3–5]. Such GISTs are aggressive
and have the potential to cause distant metastases.
Severe peritoneal dissemination is sometimes observed
at the time of diagnosis of giant gastric GISTs and is
associated with an extremely poor prognosis.
Recent progress in understanding the origin and
molecular oncology of GISTs has contributed to a rapid
improvement in their management [6]. Imatinib, which
inhibits the KIT signal transduction pathway, is considered
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a promising therapeutic agent [7]. Unresectable GISTs are
considered a systemic disease; therefore, imatinib therapy
is currently the primary treatment option in these cases
[8, 9]. However, in clinical practice, a precedent surgery is
performed for various reasons. Surgery is beneficial to
control tumor-associated complications such as abdom-
inal pain and digestive bleeding; therefore, a precedent
surgery for unresectable GISTs is sometimes necessary.
Prior to the imatinib era, surgery traditionally played
only a palliative role in patients with unresectable GISTs;
however, with the introduction of imatinib, it may be ne-
cessary to reassess the role of surgery in these cases.
Here we report the case of a patient with a giant gastric
GIST with severe peritoneal dissemination, showing
favorable progression control by postoperative imatinib
therapy following debulking surgery. This case demon-
strated that surgery can possibly play a role even in
unresectable GISTs.
Case presentation
A 49-year-old Japanese woman was referred to our hospital
with symptoms of anorexia, abdominal discomfort,
and a palpable abdominal mass. She reported a 7 kg
weight loss in a few months and had a medical
history of hypertension and hyperlipidemia as well as
a maternal history of gastric cancer. On performing a
physical examination, a palpable mass was detected in
her left upper abdominal quadrant. She had regular
bowel movements with normal stools.
A complete blood count test revealed only mild micro-
cytic hypochromic anemia (hemoglobin, 11.0 g/dL). A
blood biochemical test revealed no abnormalities, except
for an elevated lactate dehydrogenase level of 401 U/L.
Her levels of tumor markers were assessed, including
carcinoembryonic antigen, carbohydrate antigen 19-9,
and α-fetoprotein, all of which were within normal
ranges.
An abdominal X-ray revealed a diffuse opaque area in
her upper abdomen without a gastrointestinal gas
shadow; accompanying the finding, her transverse colon
was dislocated downward (Fig. 1). Endoscopy showed
compression of the posterior wall of her gastric body
along with mucosal redness. Several biopsy specimens
were taken, which showed evidence of erosive atrophic
gastritis. Contrast-enhanced computed tomography (CT)
revealed a huge mass with an irregular wall, approxi-
mately 22 cm in size, located between the posterior
gastric wall and her pancreas (Fig. 2). The mass demon-
strated heterogeneous contrast and internal low-density
components, suggestive of necrosis. The mass was
mainly supplied by her left gastric artery branches.
Moreover, many small nodules around her stomach were
observed, suggestive of enlarged lymph nodes or dissem-
inated lesions. There were no signs of hepatic masses.
Based on these findings, a mesenchymal tumor, such as
a GIST, leiomyoma, leiomyosarcoma, or a neurogenic
tumor, was suspected.
The tumor grew rapidly, and her abdominal symptoms
worsened; therefore, a semi-urgent laparotomy was
performed, although a definitive diagnosis could not be
preoperatively made. After gastrocolic ligament division,
a giant extraluminal tumor arising from the posterior
wall of her upper stomach on the lesser curvature was
noted. Furthermore, multiple white nodules, suspected
of being disseminated lesions, were widely distributed in
her greater omentum, lesser omentum, transverse meso-
colon, and retroperitoneum. Serous ascites was also seen
in the pouch of Douglas. The giant tumor adhered to
her pancreas, transverse mesocolon, and transverse
colon; however, the tumor was removed by wedge
resection of her stomach following ligation of the vessels
supplying the mass, without resecting other organs. The
radical resection of the multiple white nodules was
impossible; therefore, the nodules were resected as far as
possible.
The resected specimen was a well-circumscribed
tumor (Fig. 3a). The cut surface of the tumor revealed a
white–gray solid mass with coagulative necrosis, accom-
panying a large central cavity (Fig. 3b).
The microscopic findings of hematoxylin–eosin staining
revealed a bundle-like growth of spindle-shaped tumor
cells, with acidophilic cytoplasm and enlarged nuclei
Fig. 1 An abdominal X-ray showing a diffuse opaque area in
the upper abdomen without a gastrointestinal gas shadow; this
finding was accompanied by a downward dislocation of the
transverse colon
Fukuda et al. Journal of Medical Case Reports  (2017) 11:33 Page 2 of 7
accompanying increased chromatin levels (Fig. 4a).
Nuclear atypia was prominent, and the mitotic count was
over 150 per 50 high-power fields (Fig. 4b). Tumor cells
grew externally from the proper muscle layer of her stom-
ach (Fig. 4c). The resection margins were free of tumor
cells. Immunohistochemical staining revealed that the
tumor was positive for KIT and CD34 and negative for
desmin and S-100 protein (Fig. 5). The MIB-1 labeling
index of the tumor cells was 40 to 50 %. On histologic
examination, the resected white nodules had the same
appearance as the primary tumor and contained no com-
ponents of lymph nodes (Fig. 6). Based on these patho-
logical findings, a final diagnosis of gastric GIST with
peritoneal dissemination was made. According to the
modified Fletcher’s classification, our patient was classified
in the high-risk category [10].
Our patient had an uneventful postoperative course
and was discharged from our hospital on postoperative
day 15. Postoperative CT showed several recognizable
disseminated lesions in her abdominal cavity (Fig. 7a, b).
Treatment with imatinib at 400 mg per day was started
from 1 month postoperatively. The treatment was well
tolerated, with grade 1 eyelid swelling and grade 1 skin
rash, which improved immediately. A follow-up CT, 9
months after imatinib administration, revealed ambigu-
ous residual disseminated lesions (Fig. 7c, d). She is now
doing well, 12 months after surgery. Imatinib adminis-
tration at 400 mg per day is to be continued until dis-
ease progression is favorably controlled, with follow-up
CT planned once every 3 months.
Discussion
Complete tumor resection with negative margins is the
principle treatment for resectable GISTs, whereas ima-
tinib therapy is the principle treatment for unresectable
GISTs [11, 12]. Recent studies have demonstrated that
the prognosis of unresectable GISTs can be improved by
surgery following their conversion to resectable tumors
by imatinib therapy [13, 14]. Du et al. reported that the 2-
year progression-free survival in patients with advanced
GISTs who underwent surgery for residual lesions after
having responded to imatinib therapy was higher than that
in patients with advanced GISTs who received imatinib
therapy alone (88.4 % versus 57.7 %) [13]. Furthermore,
a b
Fig. 2 a, b Contrast-enhanced computed tomography showing a huge mass with an irregular wall, approximately 22 cm in size, located between
the posterior gastric wall and the pancreas. The mass demonstrates heterogeneous contrast and internal low-density components, suggestive of
necrosis. Moreover, many small nodules around the stomach (arrows) are observed, suggestive of enlarged lymph nodes or disseminated lesions
Fig. 3 a The resected specimen is a well-circumscribed tumor.
b The cut surface of the tumor reveals a white–gray solid mass
with coagulative necrosis, accompanying a large central cavity
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Rubió-Casadevall et al. reported that the median survival
in patients with advanced GISTs who underwent surgery
for residual lesions after having responded to imatinib
therapy was longer than that in patients with
advanced GISTs who received imatinib therapy alone
(87.6 months versus 59.9 months) [14]. However, the
effectiveness of imatinib therapy following a precedent
surgery for unresectable GISTs remains unclear. For
controlling tumor-associated complications, we performed
a precedent surgery that was non-radical and subse-
quently administered postoperative imatinib therapy
for the residual lesions. As a consequence of adminis-
tering imatinib therapy following debulking surgery,
the disease progression of the residual disseminated
lesions was favorably controlled. The present case
suggests that this treatment strategy for giant gastric




Fig. 4 a The microscopic findings of hematoxylin–eosin staining showing a bundle-like growth of spindle-shaped tumor cells. b Nuclear atypia is
prominent, and the mitotic count is over 150 per 50 high-power fields. The red arrow shows mitosis. c Tumor cells growing externally from the
proper muscle layer of the stomach
Fig. 5 Immunohistochemical staining showing that the tumor is positive for KIT (a) and CD34 (b) and negative for desmin (c) and S-100 protein (d)
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In our case, a precedent surgery was performed prior
to imatinib administration for an unresectable giant
GIST. As previously reported, serious adverse events,
such as gastrointestinal or intra-abdominal bleeding due
to tumor degeneration, occur in approximately 5 % of
giant GISTs treated with imatinib [7]. Therefore, the ap-
plication of imatinib must be carefully considered, par-
ticularly for giant GISTs. Furthermore, it is commonly
assumed that GISTs with severe peritoneal dissemin-
ation showing conversion to resectable tumors by
imatinib therapy are relatively rare. Thus, we propose
that a precedent surgery followed by imatinib therapy is
an attractive treatment option for treating giant GISTs
with severe peritoneal dissemination. As previously
reported, the development of secondary resistant lesions
was related to the amount of residual tumor, which is con-
sistent with the hypothesis that a larger number of tumor
cells are quantitatively proportional to a greater likelihood
of harboring more resistant clones [15, 16]. Therefore,
tumor debulking, as far as possible, is desirable for delay-
ing secondary resistance to imatinib.
Our case demonstrated that surgery can possibly play
a role even in unresectable GISTs. Prior to the introduc-
tion of imatinib, outcomes for patients with unresectable
GISTs were exceedingly poor, with median survival
times ranging from 10 to 20 months and a 5-year
survival of <10 % [17, 18]. With the introduction of
tyrosine kinase inhibitors, including imatinib, sunitinib,
and regorafenib, the prognosis for unresectable GISTs has
tremendously improved, and the treatment strategy for
these GISTs has considerably changed [7, 19, 20]. A
combination of surgery and tyrosine kinase inhibitor
therapy may be a promising strategy, with a large role
for surgery in unresectable GISTs in addition to re-
sectable GISTs.
At present, 11 months following imatinib adminis-
tration, the disease progression of the severe periton-
eal dissemination in our patient has been favorably
controlled. However, the appearance of resistant
lesions may become a problem later as the median
progression-free survival has been shown to be ap-
proximately 2 years for patients treated with imatinib
[6, 12]. For the early detection of disease progression,
frequent follow-up CT at 3-month intervals has been
Fig. 6 The resected white nodules at the greater omentum contain
the same spindle-shaped cells same as the primary tumor
a b
c d
Fig. 7 a, b Postoperative computed tomography, before imatinib administration, showing several recognizable disseminated lesions in the
abdominal cavity (arrows). c, d Follow-up computed tomography, 9 months after imatinib administration, showing ambiguous residual
disseminated lesions
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planned [21]. Imatinib has been planned to be con-
tinuously administered as its interruption may result
in rapid disease progression [22].
As this was a single-patient case report, these find-
ings need to be confirmed by the accumulation of
prospective evidence from more patients in multiple
institutions. Gastric GISTs are relatively rare; there-
fore, the number of patients treated in a single insti-
tution is limited. However, the current findings
provide important information that can contribute to
the development of a treatment strategy for giant gas-
tric GISTs with severe peritoneal dissemination.
Conclusions
We reported the case of a patient with a giant gastric
GIST with severe peritoneal dissemination showing
favorable progression control by imatinib therapy follow-
ing debulking surgery. The present case suggests that
imatinib therapy following debulking surgery for giant
gastric GISTs with severe peritoneal dissemination can
show dramatic effectiveness.
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